Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
NeuroMolecular Medicine
Published in: NeuroMolecular Medicine 2/2014

01-06-2014 | Original Paper

Distinct Patterns of Sirtuin Expression During Progression of Alzheimer’s Disease

Authors: Mirjam I. Lutz, Ivan Milenkovic, Günther Regelsberger, Gabor G. Kovacs

Published in: NeuroMolecular Medicine | Issue 2/2014

Login to get access

Abstract

Aging is one of the major risk factors for Alzheimer’s disease (AD). Sirtuins are associated with prolonged life span. To examine whether the expression levels of sirtuins associate with the progression of AD or not, we performed a comparative immunoblotting and immunohistochemical study of SIRT1, 3, and 5 in the entorhinal cortex and hippocampal subregions and white matter in 45 cases grouped according to Braak and Braak stages of neurofibrillary degeneration. In addition, we compared the expression levels with the local load of tau and amyloid-beta deposits, evaluated using morphometry. Our study revealed that (1) the neuronal subcellular redistribution of SIRT1 parallels the decrease in its expression, suggesting stepwise loss of neuroprotection dependent on the neuronal population; (2) in contrast to SIRT1 and 3, expression of SIRT5 increases during the progression of AD; (3) which might be related to its appearance in activated microglial cells. The complex patterns of the expression of sirtuins in relation to tissue damage should be taken into account when searching for therapies interacting with sirtuins.
Appendix
Available only for authorised users
Literature
Adori, C., Kovács, G. G., Low, P., et al. (2005). The ubiquitin-proteasome system in Creutzfeldt-Jakob and Alzheimer disease: Intracellular redistribution of components correlates with neuronal vulnerability. Neurobiol Dis., 19, 427–435.PubMedCrossRef
Alzheimer A., Stelzmann R.A., Schnitzlein H.N., Murtagh F.R. (1995). An English translation of Alzheimer’s 1907 paper, Uber eine eigenartige Erkankung der Hirnrinde. Clin Anat (New York, NY) 8: 429–431.
Baur, J. A., Pearson, K. J., Price, N. L., et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444, 337–342.PubMedCrossRef
Boily, G., Seifert, E. L., Bevilacqua, L., et al. (2008). SirT1 regulates energy metabolism and response to caloric restriction in mice. PLoS One, 3, e1759.PubMedCentralPubMedCrossRef
Boyden, S. E., & Kunkel, L. M. (2010). High-density genomewide linkage analysis of exceptional human longevity identifies multiple novel loci. PLoS One, 5, e12432.PubMedCentralPubMedCrossRef
Braak, H., & Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropatholog, 82, 239–259.CrossRef
Cai, D. (2013). Neuroinflammation and neurodegeneration in overnutrition-induced diseases. Trends Endocrinol Metabol TEM, 24, 40–47.CrossRef
Cantó, C., & Auwerx, J. (2009). Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metabol TEM, 20, 325–331.CrossRef
Chen, J., Zhou, Y., Mueller-Steiner, S., et al. (2005). SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem, 280, 40364–40374.PubMedCrossRef
Costantini, S., Sharma, A., Raucci, R., et al. (2013). Genealogy of an ancient protein family: The Sirtuins, a family of disordered members. BMC Evol Biol, 13, 60.PubMedCentralPubMedCrossRef
Dai, H., Kustigian, L., Carney, D., et al. (2010). SIRT1 activation by small molecules: Kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem, 285, 32695–32703.PubMedCentralPubMedCrossRef
De Luca, M., Rose, G., Bonafè, M., et al. (2001). Sex-specific longevity associations defined by Tyrosine Hydroxylase–Insulin–Insulin Growth Factor 2 haplotypes on the 11p15.5 chromosomal region. Exp Gerontol, 36, 1663–1671.PubMedCrossRef
Dimauro, I., Pearson, T., Caporossi, D., & Jackson, M. J. (2012). A simple protocol for the subcellular fractionation of skeletal muscle cells and tissue. BMC Res Notes, 2012(5), 513.CrossRef
Donmez, G., Wang, D., Cohen, D. E., & Guarente, L. (2010). SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell, 142, 320–332.PubMedCentralPubMedCrossRef
Duyckaerts, C., Delatour, B., & Potier, M. (2009). Classification and basic pathology of Alzheimer disease. Acta Neuropathol, 118, 5–36.PubMedCrossRef
Gan, L., & Mucke, L. (2008). Paths of convergence: Sirtuins in aging and neurodegeneration. Neuron, 58, 10–14.PubMedCrossRef
Geng, Y.-Q., Li, T–. T., Liu, X.-Y., et al. (2011). SIRT1 and SIRT5 activity expression and behavioral responses to calorie restriction. J Cell Biochem, 112, 3755–3761.PubMedCrossRef
Glorioso, C., Oh, S., Douillard, G. G., & Sibille, E. (2011). Brain molecular aging, promotion of neurological disease and modulation by sirtuin 5 longevity gene polymorphism. Neurobiol Dis, 41, 279–290.PubMedCentralPubMedCrossRef
Goedert, M., & Spillantini, M. G. (2006). A century of Alzheimer’s disease. Science, 314, 777–781.PubMedCrossRef
Hall, J. A., Dominy, J. E., Lee, Y., & Puigserver, P. (2013). The sirtuin family’s role in aging and age-associated pathologies. J Clin Invest, 123, 973–979.PubMedCentralPubMedCrossRef
Hisahara, S., Chiba, S., Matsumoto, H., et al. (2008). Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc Natl Acad Sci USA, 105, 15599–15604.PubMedCentralPubMedCrossRef
Höftberger, R., Fink, S., Aboul-Enein, F., et al. (2010). Tubulin polymerization promoting protein (TPPP/p25) as a marker for oligodendroglial changes in multiple sclerosis. Glia, 58, 1847–1857.PubMedCrossRef
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012). Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol, 13, 225–238.PubMed
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., et al. (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 425, 191–196.PubMedCrossRef
Imai, S., & Guarente, L. (2010). Ten years of NAD-dependent SIR2 family deacetylases: Implications for metabolic diseases. Trends Pharmacol Sci, 31, 212–220.PubMedCentralPubMedCrossRef
Jin, Q., Yan, T., Ge, X., et al. (2007). Cytoplasm-localized SIRT1 enhances apoptosis. J Cell Physiol, 213, 88–97.PubMedCrossRef
Julien, C., Tremblay, C., Emond, V., et al. (2009). Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol, 68, 48–58.PubMedCentralPubMedCrossRef
Kim, D., Nguyen, M. D., Dobbin, M. M., et al. (2007). SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J, 26, 3169–3179.PubMedCentralPubMedCrossRef
Körner, S., Böselt, S., Thau, N., et al. (2013). Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: Neuroprotective or neurotoxic properties of Sirtuins in ALS? Neurodegener Dis, 11, 141–152.PubMedCrossRef
Li, X., Zhang, S., Blander, G., et al. (2007). SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell, 28, 91–106.PubMedCrossRef
Luo, J., Nikolaev, A. Y., Imai, S., et al. (2001). Negative control of p53 by Sir2α promotes cell survival under stress. Cell, 107, 137–148.PubMedCrossRef
Lynch, C. J., Shah, Z. H., Allison, S. J., et al. (2010). SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53. PLoS One, 5, e13502.PubMedCentralPubMedCrossRef
Mahlknecht, U., Ho, A. D., Letzel, S., & Voelter-Mahlknecht, S. (2006). Assignment of the NAD-dependent deacetylase sirtuin 5 gene (SIRT5) to human chromosome band 6p23 by in situ hybridization. Cytogenet Genome Res, 112, 208–212.PubMedCrossRef
Matsushita, N., Yonashiro, R., Ogata, Y., et al. (2011). Distinct regulation of mitochondrial localization and stability of two human Sirt5 isoforms. Genes cells, 16, 190–202.PubMedCrossRef
Michishita, E., Park, J. Y., Burneskis, J. M., et al. (2005). Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell, 16, 4623–4635.PubMedCentralPubMedCrossRef
Mirra, S. S., Heyman, A., McKeel, D., et al. (1991). The consortium to establish a registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology, 41, 479–486.PubMedCrossRef
Misiak, B., Leszek, J., & Kiejna, A. (2012). Metabolic syndrome, mild cognitive impairment and Alzheimer’s disease–the emerging role of systemic low-grade inflammation and adiposity. Brain Res Bull, 89, 144–149.PubMedCrossRef
Montine, T. J., Phelps, C. H., Beach, T. G., et al. (2012). National institute on Aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol, 123, 1–11.PubMedCentralPubMedCrossRef
Mrak, R., & Griffin, W. (2005). Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging, 26, 349–354.PubMedCrossRef
Onyango, P., Celic, I., McCaffery, J. M., et al. (2002). SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci USA, 99, 13653–13658.PubMedCentralPubMedCrossRef
Oppenheimer, H., Gabay, O., Meir, H., et al. (2012). 75-kd sirtuin 1 blocks tumor necrosis factor α-mediated apoptosis in human osteoarthritic chondrocytes. Arthritis Rheum, 64, 718–728.PubMedCentralPubMedCrossRef
Panza, F., Frisardi, V., Capurso, C., et al. (2010). Metabolic syndrome and cognitive impairment: Current epidemiology and possible underlying mechanisms. J Alzheimer’s Dis, 21, 691–724.
Park, J. (2013). SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol Cell, 50, 919–930.PubMedCrossRef
Peng, C., Lu, Z., Xie, Z., et al. (2011). The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteom, 10(M111), 012658.
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010). Microglia in neurodegenerative disease. Nat Rev Neurol, 6, 193–201.PubMedCrossRef
Polito, L., Kehoe, P. G., Forloni, G., & Albani, D. (2010). The molecular genetics of sirtuins: Association with human longevity and age-related diseases. Int J Mol Epidemiol Genetics, 1, 214–225.
Qin, W., Yang, T., Ho, L., et al. (2006). Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem, 281, 21745–21754.PubMedCrossRef
Ramadori, G., Lee, C. E., Bookout, A. L., et al. (2008). Brain SIRT1: Anatomical distribution and regulation by energy availability. J Neurosci, 28, 9989–9996.PubMedCentralPubMedCrossRef
Rice, C. M., Sun, M., Kemp, K., et al. (2012). Mitochondrial sirtuins–a new therapeutic target for repair and protection in multiple sclerosis. Eur J Neurosci, 35, 1887–1893.PubMedCrossRef
Rose, G., Dato, S., Altomare, K., et al. (2003). Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp Gerontol, 38, 1065–1070.PubMedCrossRef
Sakamoto, J., Miura, T., Shimamoto, K., & Horio, Y. (2004). Predominant expression of Sir2α, an NAD-dependent histone deacetylase, in the embryonic mouse heart and brain. FEBS Lett, 556, 281–286.PubMedCrossRef
Schwer, B., North, B. J., Frye, R. A., et al. (2002). The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol, 158, 647–657.PubMedCentralPubMedCrossRef
Sugino, T., Maruyama, M., Tanno, M., et al. (2010). Protein deacetylase SIRT1 in the cytoplasm promotes nerve growth factor-induced neurite outgrowth in PC12 cells. FEBS Lett, 584, 2821–2826.PubMedCrossRef
Tanno, M., Sakamoto, J., Miura, T., et al. (2007). Nucleocytoplasmic shuttling of the NAD + -dependent histone deacetylase SIRT1. J Biol Chem, 282, 6823–6832.PubMedCrossRef
Thal, D. R., Rub, U., Orantes, M., & Braak, H. (2002). Phases of A-deposition in the human brain and its relevance for the development of AD. Neurology, 58, 1791–1800.PubMedCrossRef
Vasiljevic, M., Heisler, F. F., Hausrat, T. J., et al. (2012). Spatio-temporal expression analysis of the calcium-binding protein calumenin in the rodent brain. Neuroscience, 202, 29–41.PubMedCentralPubMedCrossRef
Vaziri, H., Dessain, S. K., Eaton, E. N., et al. (2001). hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase. Cell, 107, 149–159.PubMedCrossRef
Wood, J. G., Rogina, B., Lavu, S., et al. (2004). Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature, 430, 686–689.PubMedCrossRef
Zhang, Z., Tan, M., Xie, Z., et al. (2011). Identification of lysine succinylation as a new post-translational modification. Nat Chem Biol, 7, 58–63.PubMedCentralPubMedCrossRef
Metadata
Title
Distinct Patterns of Sirtuin Expression During Progression of Alzheimer’s Disease
Authors
Mirjam I. Lutz
Ivan Milenkovic
Günther Regelsberger
Gabor G. Kovacs
Publication date
01-06-2014
Publisher
Springer US
Published in
NeuroMolecular Medicine / Issue 2/2014
Print ISSN: 1535-1084
Electronic ISSN: 1559-1174
DOI
https://doi.org/10.1007/s12017-014-8288-8

Other articles of this Issue 2/2014

NeuroMolecular Medicine 2/2014 Go to the issue

Original Paper

Oct-2 Transcription Factor Binding Activity and Expression Up-Regulation in Rat Cerebral Ischaemia is Associated with a Diminution of Neuronal Damage In Vitro

Original Paper

ADHD Diagnosis May Influence the Association between Polymorphisms in Nicotinic Acetylcholine Receptor Genes and Tobacco Smoking

Original Paper

Blockade of Nav1.8 Currents in Nociceptive Trigeminal Neurons Contributes to Anti-trigeminovascular Nociceptive Effect of Amitriptyline

Original Paper

Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down’s Syndrome

Original Paper

Correction of the Middle Eastern M712T Mutation Causing GNE Myopathy by Trans-Splicing

Review Paper

Rett Syndrome and MeCP2